TCGA-GC-A6I1-01A-12R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0
- os_event
- true
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- ALLOGRAFT_REJECTION+0.600
- INTERFERON_GAMMA_RESPONSE+0.590
- MYC_TARGETS_V2+0.540
- INFLAMMATORY_RESPONSE+0.530
- MYC_TARGETS_V1+0.530
- IL6_JAK_STAT3_SIGNALING+0.510
- TNFA_SIGNALING_VIA_NFKB+0.490
- MTORC1_SIGNALING+0.470
- UNFOLDED_PROTEIN_RESPONSE+0.460
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.350
- NOTCH_SIGNALING-0.270
- ESTROGEN_RESPONSE_EARLY-0.250
- MITOTIC_SPINDLE-0.230
- UV_RESPONSE_DN-0.200
- MYOGENESIS-0.130
- BILE_ACID_METABOLISM-0.110
- APICAL_SURFACE-0.080
- SPERMATOGENESIS-0.070
- WNT_BETA_CATENIN_SIGNALING-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_GJNCYABP | ATRT | — | 0.920 |
| 2 | TCGA-DK-A3WW-01A-22R-A23N-07 | — | — | 0.916 |
| 3 | TCGA-BA-A6DJ-01A-11R-A30B-07 | — | — | 0.912 |
| 4 | 8f1213be-da41-4cd6-97b2-f9fce1ea00ff | — | — | 0.911 |
| 5 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.909 |
| 6 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.898 |
| 7 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.896 |
| 8 | MDT-AP-2036 | Med | Medulloblastoma | 0.896 |
| 9 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.896 |
| 10 | MNG1188 | — | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.530 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.510 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.460 | Idelalisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.340 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |